Trial reportAntimicrobial agents and chemotherapy2000
A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.
Trial report in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 54 citations in OpenAlex.
- Endothelial Transcytosis in Acute Lung Injury: Emerging Mechanisms and Therapeutic Approaches.Frontiers in physiology · 2022Review
- Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis.Frontiers in pharmacology · 2022Article
- The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia.Trends in cardiovascular medicine · 2022Review
- Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.Molecules (Basel, Switzerland) · 2019Review
- A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?Bioinorganic chemistry and applications · 2017Review
- Sepsis: in search of cure.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2016Review
- Sepsis and septic shock.Nature reviews. Disease primers · 2016Review
- CD1d- and MR1-Restricted T Cells in Sepsis.Frontiers in immunology · 2015Review
- Treatment and prophylaxis of melioidosis.International journal of antimicrobial agents · 2014Review
- Animal models of sepsis.Virulence · 2014Review
- Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology?Critical care (London, England) · 2013Review
- Positive effect of septimeb™ on mortality rate in severe sepsis: a novel non antibiotic strategy.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2012Article
- In vitro anti-inflammatory and anti-coagulant effects of antibiotics towards Platelet Activating Factor and thrombin.Journal of inflammation (London, England) · 2011Article
- The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses.Biochimie · 2010Review
- Pharmacological approach to acute pancreatitis.World journal of gastroenterology · 2008Review
- Melioidosis: epidemiology, pathophysiology, and management.Clinical microbiology reviews · 2005Review
- Relationship between cytokine mRNA expression and organ damage following cecal ligation and puncture.World journal of gastroenterology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Platelet-activating factor (PAF) is a potent endogenous proinflammatory mediator implicated in the pathogenesis of septic shock. A double-blind randomized placebo-controlled trial of an intravenous PAF receptor antagonist (lexipafant) was conducted with 131 adult Thai patients with suspected severe sepsis (66 of whom had positive blood cultures). Detailed serial clinical, biochemical, and cytokine measurements were performed. Lexipafant treatment was well tolerated. The 28-day mortality in the lexipafant group (61.4%) was similar to that in the placebo group (62.6%). There was also no evidence that lexipafant affected clinical or biochemical measures of disease severity or the profile of sequentially measured plasma cytokine levels. PAF may not have an important role in the pathogenesis of severe sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.